“Comparison of the Efficacy of Generation 1 and 2 Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients with EGFR Positive Mutations” (2021) Indian Journal of Forensic Medicine & Toxicology, 15(3), pp. 4316–4324. doi:10.37506/ijfmt.v15i3.15970.